Windtree Therapeutics completes national phase filings for istaroxime

Windtree Therapeutics (WINT) announced that the Company has completed national phase filings of patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. “Windtree continues to prepare for the potential of istaroxime in treating cardiogenic shock patients by expanding and strengthening our patent estate,” said Craig Fraser, Chairman and Chief Executive Officer of Windtree. “Unique aspects of istaroxime are utilized in our strategy for intellectual property and positive clinical development has helped bring these aspects to light.”